Alogliptin benzoate for the treatment of type 2 diabetes (Q37980541)

26 August 2017

Alogliptin benzoate for the treatment of type 2 diabetes (English)

1 reference

26 August 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

Marc Rendell

1

1 reference

26 August 2017

Andjela Drincic

series ordinal

2

1 reference

26 August 2017

Radha Andukuri

series ordinal

3

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 February 2012

1 reference

Expert Opinion on Pharmacotherapy

26 August 2017

1 reference

26 August 2017

13

1 reference

26 August 2017

4

1 reference

26 August 2017

553-563

1 reference

The biology of incretin hormones

26 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

GIP biology and fat metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Hypersecretion of Gastric Inhibitory Polypeptide Following Oral Glucose in Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

The role of incretins in glucose homeostasis and diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Vildagliptin: a review of its use in the management of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjec

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Alogliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Postmenopausal hormone therapy for disease prevention: have we learned any lessons from the past?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

The safety of incretin-based therapies--review of the scientific evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Do incretin-based therapies cause acute pancreatitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Long-term effects of intensive glucose lowering on cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

Counterpoint: Intensive glucose control and mortality in ACCORD--still looking for clues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656088

10.1517/14656566.2012.656088

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference